Baird Reiterates Outperform on CARISMA Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Jack Allen has reiterated an Outperform rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained a $10 price target.
June 28, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst has reiterated an Outperform rating on CARISMA Therapeutics and maintained a $10 price target.
The reiteration of an Outperform rating by Baird analyst Jack Allen indicates a positive outlook for CARISMA Therapeutics. The maintained price target of $10 also suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100